[ORGANIZATION]
TransCode Therapeutics
Featured in 2 tracked stories · first seen
Situations
Natera, Inc. business and market developments
2 clusters · 4 sources · last updated
Latest: Natera, Inc. sees price target hike and new strategic partnership
Natera, Inc. has experienced growth in both its market valuation and strategic clinical applications. In September 2026, CEO Steven Chapman reported strong second-quarter performance, including nearly 40% year-over-year
Also covered in
-
CK Life Sciences narrows H1 losses by 81%
[BUSINESS] · 2 sources ·